Full text is available at the source.
Abstract
Mazdutide is a dual GLP-1 and glucagon receptor agonist that may provide stronger metabolic benefits for patients with Type 2 diabetes mellitus.
- Type 2 diabetes mellitus is often associated with obesity and significant metabolic complications.
- GLP-1 receptor agonists, such as dulaglutide, can improve blood sugar levels and contribute to modest weight loss.
- Many patients fail to achieve their treatment goals with current GLP-1 receptor agonists.
- Mazdutide may enhance metabolic outcomes beyond those achieved with existing treatments.
Simplified